false 0001831915 0001831915 2024-09-09 2024-09-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

September 9, 2024

 

 

Cytek Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40632   47-2547526
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

47215 Lakeview Boulevard  
Fremont, California   94538
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (877) 922-9835

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   CTKB   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 9, 2024, Paul Christopher Williams submitted his resignation from his position as the Chief Operating Officer of Cytek Biosciences, Inc. (the “Company”), effective as of September 27, 2024, to pursue another career opportunity.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Cytek Biosciences, Inc.
Date: September 12, 2024     By:  

 /s/ Wenbin Jiang

       Wenbin Jiang, Ph.D.
       President and Chief Executive Officer
v3.24.2.u1
Document and Entity Information
Sep. 09, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001831915
Document Type 8-K
Document Period End Date Sep. 09, 2024
Entity Registrant Name Cytek Biosciences, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40632
Entity Tax Identification Number 47-2547526
Entity Address, Address Line One 47215 Lakeview Boulevard
Entity Address, City or Town Fremont
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94538
City Area Code (877)
Local Phone Number 922-9835
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol CTKB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Cytek Biosciences Charts.
Cytek Biosciences (NASDAQ:CTKB)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Cytek Biosciences Charts.